NEW YORK, March 4 (Reuters) - UniQure's trial design for its gene therapy for Huntington's disease did not offer sufficient proof that the drug slowed disease progression, a top U.S. Food and Drug ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Pivotal study shows no clear benefit for the common endoscopic procedure in this patient group. Experts say the new data ...

Study of 600,000 US military veterans shows that those who took anti-obesity medications were less likely to develop some complications of substance-use disorders.

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction - and help people who already have one, a ...

An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...

First-ever randomized, placebo-controlled Phase 1 trial - published in The Lancet Microbe - supports SNIPR001’s safety, tolerability, and restriction to the gastrointestinal tract in healthy ...

Early detection tests are on the market in Australia and overseas but so far there’s little evidence they reduce deaths and ...

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost ...

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Drinks high in potassium include fruit juices, such as prune, pomegranate, tomato, orange, and coconut. Other drinks include ...